» Articles » PMID: 32980462

Evolutionary Artificial Intelligence Based Peptide Discoveries for Effective Covid-19 Therapeutics

Overview
Publisher Elsevier
Date 2020 Sep 27
PMID 32980462
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

An epidemic caused by COVID-19 in China turned into pandemic within a short duration affecting countries worldwide. Researchers and companies around the world are working on all the possible strategies to develop a curative or preventive strategy for the same, which includes vaccine development, drug repurposing, plasma therapy, and drug discovery based on Artificial intelligence. Therapeutic approaches based on Computational biology and Machine-learning algorithms are specially considered, with a view that these could provide a fast and accurate outcome in the present scenario. As an effort towards developing possible therapeutics for COVID-19, we have used machine-learning algorithms for the generation of alignment kernels from diverse viral sequences of Covid-19 reported from India, China, Italy and USA. Using these diverse sequences we have identified the conserved motifs and subsequently a peptide library was designed against them. Of these, 4 peptides have shown strong binding affinity against the main protease of SARS-CoV-2 (M) and also maintained their stability and specificity under physiological conditions as observed through MD Simulations. Our data suggest that these evolutionary peptides against COVID-19 if found effective may provide cross-protection against diverse Covid-19 variants.

Citing Articles

Leveraging Evolutionary Immunology in Interleukin-6 and Interleukin-17 Signaling for Lung Cancer Therapeutics.

Khilwani R, Singh S ACS Pharmacol Transl Sci. 2024; 7(12):3658-3670.

PMID: 39698267 PMC: 11650734. DOI: 10.1021/acsptsci.4c00412.


The Artificial Intelligence-Powered New Era in Pharmaceutical Research and Development: A Review.

Suriyaamporn P, Pamornpathomkul B, Patrojanasophon P, Ngawhirunpat T, Rojanarata T, Opanasopit P AAPS PharmSciTech. 2024; 25(6):188.

PMID: 39147952 DOI: 10.1208/s12249-024-02901-y.


Recent advances in the exploration and discovery of SARS-CoV-2 inhibitory peptides from edible animal proteins.

Kong X, Wang W, Zhong Y, Wang N, Bai K, Wu Y Front Nutr. 2024; 11:1346510.

PMID: 38389797 PMC: 10883054. DOI: 10.3389/fnut.2024.1346510.


Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design.

Vora L, Gholap A, Jetha K, Thakur R, Solanki H, Chavda V Pharmaceutics. 2023; 15(7).

PMID: 37514102 PMC: 10385763. DOI: 10.3390/pharmaceutics15071916.


Opportunities and challenges in application of artificial intelligence in pharmacology.

Kumar M, Nguyen T, Kaur J, Singh T, Soni D, Singh R Pharmacol Rep. 2023; 75(1):3-18.

PMID: 36624355 PMC: 9838466. DOI: 10.1007/s43440-022-00445-1.


References
1.
Lurie N, Saville M, Hatchett R, Halton J . Developing Covid-19 Vaccines at Pandemic Speed. N Engl J Med. 2020; 382(21):1969-1973. DOI: 10.1056/NEJMp2005630. View

2.
Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y . Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020; 10(5):766-788. PMC: 7102550. DOI: 10.1016/j.apsb.2020.02.008. View

3.
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M . Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3):269-271. PMC: 7054408. DOI: 10.1038/s41422-020-0282-0. View

4.
de Wit E, Feldmann F, Cronin J, Jordan R, Okumura A, Thomas T . Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci U S A. 2020; 117(12):6771-6776. PMC: 7104368. DOI: 10.1073/pnas.1922083117. View

5.
Xu X, Han M, Li T, Sun W, Wang D, Fu B . Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020; 117(20):10970-10975. PMC: 7245089. DOI: 10.1073/pnas.2005615117. View